Exploratory use of ultrasound to determine whether demyelination following carpal tunnel syndrome co-exists with axonal degeneration

Xue Deng1, Lai-Heung Phoebie Chau1, Suk-Yee Chiu1, Kwok-Pui Leung1, Sheung-Wai Li2, Wing-Yuk Ip1,*
1 Department of Orthopedics & Traumatology, The University of Hong Kong, Hong Kong Special Administrative Region, China
2 Clinical Electro-diagnostic Unit, Tung Wah Hospital, Hong Kong Special Administrative Region, China
3 Department of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China

Abstract
Carpal tunnel syndrome (CTS) accompanied by secondary axonal degeneration cannot be clearly discriminated using the current cross-validated ultrasound severity classification system. This study aimed at exploring cut-off values of ultrasound parameters, including wrist cross-sectional area (W-CSA), wrist perimeter (W-P), ratio of cross-sectional area (R-CSA) and perimeter (R-P), changes of CSA and P from wrist to one third distal forearm (ΔCSA&P) for differentiation. Seventy-three patients (13 male and 60 female) were assigned into group A (demyelination only, n = 40) and group B (demyelination with secondary axonal degeneration, n = 33) based on the outcomes of nerve conduction studies (NCS). Receiver Operating Characteristics (ROC) curves were plotted to obtain sensitivity, specificity, and accuracy of cut-off values for all the ultrasound parameters. The overall identified cut-off values (W-CSA 12.0 mm², W-P 16.27 mm, R-CSA 1.85, R-P 1.48, ΔCSA 6.98 mm², ΔP 5.77 mm) had good sensitivity (77.1–88.6%), fair specificity (40–62.2%) and fair-to-good accuracy (0.676–0.758). There were also significant differences in demographics (age and severity gradation, P < 0.001), NCS findings (wrist motor latency and conduction velocity, P < 0.0001; wrist motor amplitude, P < 0.05; distal sensory latency, P < 0.05; sensory amplitude, P < 0.001) and ultrasound measurements (W-CSA, W-P, R-CSA, R-P, ΔCSA&P, ΔP < 0.05) between groups. These findings suggest that ultrasound can be potentially used to differentiate demyelinating CTS with secondary axonal degeneration and provide better treatment guidance.

Key Words: carpal tunnel syndrome; nerve conduction studies; ultrasound; receiver operating characteristic curve; peripheral nerve compression injury; ultrasonography; neural conduction; axonal degeneration; neural regeneration

Introduction
Carpal tunnel syndrome (CTS) is the mostly reported peripheral nerve compression injury at the wrist with an estimated incidence rate of 8% across life-span (Rempel et al., 1998; Werner and Andary, 2002). Clinically, it usually manifests numbness, tingling, and/or pain in the sensory median nerve-innervated area of the hand (Ntani et al., 2013). CTS is pathologically a disorder with segmental demyelination, and secondary axonal degeneration may co-exist following demyelination (Caetano, 2003). It is of great clinical significance to distinguish this as the optimal treatment may differ with or without axonal degeneration. However, there are many challenges in the discrimination using conventional methods. Nerve conduction studies (NCS) combined with clinical tests, e.g., Phalen’s test, Tinel’s sign test (Miedany et al., 2008; Baiee et al., 2015) are the gold standard in the diagnosis of CTS. NCS can only differentiate axonal degeneration by comparing distal and proximal evoked responses (Lesser et al., 1995). Palmar stimulation is usually not taken as a distal record, resulting in a difficulty in differentiation (Caetano, 2003). In addition, conduction block and temporal dispersion may also blur its accuracy because both may also cause amplitude drop (Kiernan, 1999). Needle electromyography and nerve biopsy can provide more sensitive and accurate information in the determination of axonal degeneration, but they are restricted in the clinical practice (Werner and Andary, 2011).

To overcome these shortcomings, ultrasound has been cross-validated by NCS in the diagnosis and severity grading of CTS (Cartwright et al., 2012; Tai et al., 2012; Fujimoto et al., 2015). It can complementarily provide anatomical information, including thickness of retinaculum, echogenicity, and cross-sectional area (CSA) of the median nerve to reflect the severity of CTS (Klauser et al., 2015). Previous studies in which NCS was used for diagnosis confirmation and severity classification have validated the cut-off values of ultrasound parameters, e.g., CSA (Wong et al., 2002; Baiee et al., 2015; Fujimoto et al., 2015; Zhang et al., 2015). However, it remains unknown about the cut-off values of the parameters of the current NCS-ultrasound severity classification system in the differentiation of axonal degeneration. A previous NCS study revealed that over half of the patients with mild and moderate CTS developed secondary axonal degeneration (Caetano, 2003). This ambiguity may constrain the accuracy of treatment prescription. It is necessary to explore the cut-off values to compensate the deficit.

Baiee et al. (2015) reported that median nerve swelling can induce lower amplitude of the compound motor action potential (CMAP) and sensory nerve action potential (SNAP) of the median nerve, suggesting the potential axonal degener...
eration with the enlarged CSA. We hypothesized that there were cut-off values of ultrasound parameters with acceptable sensitivity, specificity, and accuracy for differentiating CTS accompanied by secondary axonal degeneration.

The purpose of this study was to explore the cut-off values of ultrasound parameters used to differentiate demyelinating CTS accompanied by axonal degeneration. To our best knowledge, this is the first study in this field. Its findings can help to clarify the pathological progress, providing more accurate treatment guidance. The NCS-ultrasound technique has great potential for application in the general clinical practice owing to the non-invasiveness, low cost, and great efficiency of ultrasound.

**Subjects and Methods**

**Subjects**

This is a non-randomized, cross-sectional cohort study. It was approved by the Institutional Review Board of the University of Hong Kong/Hospital Authorities in Hong Kong West (HKU/HA HKW IRB, Ref. Number: UW17-129), Hong Kong Special Administrative Region, China and performed in strict accordance with the Declaration of Helsinki. Written informed consent were obtained from all patients. They were initially screened at hand clinic by an experienced hand surgeon, and then referred to a physician subspecialized in NCS and ultrasound for diagnosis confirmation and severity gradient. The diagnostic criteria for CTS severity gradation was in accordance with Bland’s classification (Bland, 2000).

Seventy-three patients with CTS who received treatment between April 2014 and September 2017 were included in this study. The inclusion criteria were set as follows: (1) Asian male or female subjects at the age of 40–75 years; (2) right handedness; (3) preliminary diagnosis as CTS based on NCS outcomes in combination with positive clinical tests; (4) a history of clinical signs and symptoms, e.g., numbness, tingling, and/or pain for more than 3 months in the median nerve-innervated area of the hand and/or fingers. Subjects were excluded under one of more of the following conditions: (1) anatomical abnormalities (e.g., a bifid structure of median nerve) at the wrist displayed on ultrasound image; (2) comorbidities, e.g., diabetes mellitus, cardiovascular disease, respiratory disease, neurological disease, rheumatoid arthritis, gout, wrist fracture, entrapment of the nerves other than median nerve, cervical radiculopathy, myelopathy, and peripheral neuropathy; (3) a surgical history at the wrist. Since the motor conduction test is less sensitive than the sensory test in the evaluation of CTS, so sensory nerve-innervated area of the hand and/or fingers. Subjects with conduction block (CMAP amplitude drop ≤ 20%) were excluded (Weber, 1997; Kiernan, 1999). 10 μV were cut-off values of ultrasound parameters with acceptable sensitivity, specificity, and accuracy for differentiating CTS accompanied by secondary axonal degeneration. To our best knowledge, this is the first study in this field. Its findings can help to clarify the pathological progress, providing more accurate treatment guidance. The NCS-ultrasound technique has great potential for application in the general clinical practice owing to the non-invasiveness, low cost, and great efficiency of ultrasound.

**Procedures of nerve conduction studies**

An NCS machine (Nicolet, Middletown, WI, USA) was utilized following standard practice: supramaximal percutaneous stimulation and surface electrode recording were performed. Skin temperature was maintained above 32°C. Motor evoked potential of the median nerve was measured by stimulation at the palm (4 cm distal to the wrist), the wrist (6.5 cm proximal to the thenar muscle) and the elbow (just above the crease of antecubital fossa, lateral to the medial epicondyle and medial to the biceps tendon) respectively (Figure 1A). Whereas motor evoked potential of the ulnar nerve was measured by stimulation at the wrist (7 cm proximal to the belly of the abductor digiti minimi muscle), below (3 to 4 cm distal to the medial epicondyle) and above elbow (6 to 7 cm proximal to the medial epicondyle) respectively (Figure 1B). Sensory evoked potentials were obtained by orthodromic stimulation at the wrist and recording from the 2nd finger (median nerve) or the 5th fingers (ulnar nerve) with ring electrodes at a distance of 12 or 14 cm in terms of the upper limb length and hand size (Figure 1C).

**Ultrasound procedures**

A real-time ultrasound scanner (MyLabTM Twice, ESAOTE, Maastricht, the Netherland) with a 4–13 MHz linear array transducer was used for ultrasound scanning by the same physician skilful in musculoskeletal ultrasonography soon after NCS assessment. Subjects were seated on a plinth facing the examiner, with hands resting in a horizontal supine position and fingers semi-extended. Transverse scans of the median nerve would be performed from the distal segment of the forearm to the tunnel outlet. Cross-sectional area (CSA) and perimeter (P) measurements at the distal and proximal levels were traced continuously by outlining the hyperechoic epineurium at the correspondent sites: (1) distal level was taken at the tunnel or level of radial head (Figure 2A) while (2) proximal level was taken at one third distal forearm (DF-CSA, DF-P) (Figure 2B). Then, ratios (R-CSA and R-P) were calculated by dividing wrist over one third distal forearm measurements. Changes from wrist to one third distal forearm (ΔCSA and ΔP) were obtained via wrist minus one third distal forearm measurements. These measurement sites were taken because many studies have reported high sensitivity and specificity using CSA at tunnel inlet, while much reproducible landmark in the proximal third of pro-
nator quadratus muscle in the distal forearm (Duncan et al., 1999; Wong et al., 2002, 2004; Wiesler et al., 2006; Mondelli et al., 2008; Klauser et al., 2009, 2015; Miyamoto et al., 2014).

Data analysis
SPSS 24.0 software (IBM, Armonk, NY, USA) was used to analyze the data. Independent samples t-test was used to investigate the differences in demographics (age), NCS findings and ultrasound parameters between groups A and B. Paired t-test was used to compare palmar and wrist CMAP amplitude within groups. Mann-Whitney U test was applied to explore differences of severity of CTS between groups A and B. Pearson’s chi-square test was used to examine categorical variables (gender, wrist site) between groups A and B. The area under the receiver operating characteristic curves (AUROC) was used to figure out the cut-off values of ultrasound parameters to explore acceptable sensitivity and specificity.

Results
Baseline data
Seventy-three patients were included in this study. Among these patients, 40 patients (45 hands) and 33 patients (35 hands) were assigned into group A (demyelination only) and group B (demyelination plus secondary axonal degeneration) respectively. Gender (Pearson’s chi-square value = 1.589, P = 0.208) and handedness (Pearson’s chi-square value = 0.288, P = 0.591) were not significantly associated with grouping. There were significant differences in age (t = −3.703, P < 0.001) and severity grade (Z = −3.774, P < 0.001) between groups. Overall, the recruited hands in the group A were less severe than those in the group B (Table 1).

Findings of NCS
As shown in Table 2, there were significant differences in motor latency (t = −4.35, P < 0.0001), CMAP amplitude (t = 2.49, P = 0.015), and conduction velocity (t = 4.106, P < 0.0001) of the median motor nerve at the wrist between groups A and B. Significant differences in motor latency (t = −4.885, P < 0.0001) and CMAP amplitude (t = 2.785, P = 0.007) of the median motor nerve at the elbow between groups. There were no significant differences in motor latency (t = −1.746, P = 0.085) and CMAP amplitude (t = 1.25, P = 0.215) of the median motor nerve at the palmar site between groups. In the group B, CMAP amplitude of the median motor nerve at the palmar site was significantly higher than that at the wrist (t = 3.32, P = 0.002), but there was no significant difference in CMAP amplitude of the median motor nerve between palmar site and wrist in the group A (t = −0.186, P = 0.854). There were significant differences in the distal sensory latency (t = −3.17, P = 0.003) and SNAP amplitude (t = 7.88, P < 0.0001) of the median sensory nerve between groups A and C. No significant difference in conduction velocity (t = 1.95, P = 0.057) of the median sensory nerve at the wrist was found between groups A and B. As shown in Table 3, there were no significant differences in all variables of the evoked potentials of ulnar motor and sensory nerves, except SNAP amplitude at the wrist (t = 2.88, P = 0.005) between groups A and B. The outcomes of NCS variables of the median nerve at the wrist in the group A were superior to those in the group B while the ulnar nerves remained normal in both groups.

Findings of ultrasound parameters
There were significant differences in wrist cross-sectional area (W-CSA; t = −3.17, P = 0.003), wrist perimeter (W-P; t = −3.68, P = 0.001), ratio of cross-sectional area of wrist over one third distal forearm (R-CSA; t = −3.68, P = 0.001), ratio of perimeter of wrist over one third distal forearm (R-P; t = −2.65, P = 0.01), changes of cross-sectional area from wrist to one third distal forearm (ΔCSA; t = −3.58, P = 0.001) and changes of perimeter from wrist to one third distal forearm

Table 1 Baseline data of the included 73 patients with carpal tunnel syndrome

| Variables                  | Group A (n = 40) | Group B (n = 33) |
|----------------------------|-----------------|-----------------|
| Gender                     |                 |                 |
| Female (n)                 | 31              | 29              |
| Male (n)                   | 9               | 4               |
| Age (year, mean±SD)        | 58.72±8.40      | 65.3±7.96*      |
| Handedness                 |                 |                 |
| Right (n)                  | 23              | 20              |
| Left (n)                   | 22              | 15              |
| Severity gradation         |                 |                 |
| Mild (n)                   | 20              | 9               |
| Mild to moderate (n)        | 8               | 0               |
| Moderate (n)               | 14              | 7               |
| Moderate to severe (n)      | 2               | 6               |
| Severe (n)                 | 2               | 13*             |

*P < 0.001, vs. group A. Independent samples t-test was used for age comparison and Mann-Whitney U test for comparison of severity gradation.

Table 2 Nerve conduction studies of the median nerve in patients with carpal tunnel syndrome

| Variables                  | Group A (n = 40) | Group B (n = 33) |
|----------------------------|-----------------|-----------------|
| Median motor nerve         |                 |                 |
| Palmar DML (ms)            | 2.00±0.28       | 2.00±0.21       |
| Palmar CMAP (mV)           | 8.59±2.52       | 7.68±2.26       |
| Wrist ML (ms)              | 4.79±1.16       | 6.25±1.62***    |
| Wrist CMAP (mV)            | 8.28±2.49       | 7.00±2.00**     |
| Wrist MCV (m/s)            | 27.00±7.60      | 20.40±6.17***   |
| Elbow ML (ms)              | 8.47±0.98       | 10.2±1.68***    |
| Elbow CMAP (mV)            | 7.91±2.20       | 6.54±1.83*      |
| Elbow MCV (m/s)            | 53.23±4.32      | 53.54±5.98      |
| Median sensory nerve       |                 |                 |
| DML (ms)                   | 3.22±0.43       | 3.61±0.46*      |
| SNAP (μV)                  | 12.82±4.41      | 6.21±2.23**     |
| MCV (m/s)                  | 36.39±6.3       | 33.74±4.23      |

*P < 0.05, **P < 0.001, ***P < 0.0001, vs. group A. Data are expressed as the mean ± SD (independent samples t-test). DML: Distal motor latency; CMAP: compound motor action potential; ML: motor latency; MCV: motor conduction velocity; DLS: distal sensory latency; SNAP: sensory nerve action potential; SCV: sensory conduction velocity.
(ΔP; t = −3.406, P = 0.001) while no significant differences in DF-CSA (t = 0.29, P = 0.77) and DF-P (t = −0.33, P = 0.74) (Table 4). The overall outcomes of ultrasound parameters in the group A were inferior to those in the group B.

Cut-off values, sensitivity, specificity, and ROC curves

The sensitivity and specificity of the cut-off values measured by ultrasound were plotted via ROC curves (Figure 3A–C). All the ultrasound parameters indicated good sensitivity, fair specificity and fair to good accuracy to differentiate demyelination from axonal degeneration among patients with CTS. As shown in Tables 5 and 6, the AUC of W-CSA was 0.71 at 12.00 mm², with sensitivity of 80% and specificity of 48.9%; the AUC of the W-P was 0.748 at 16.27 mm, with
Table 3 Nerve conduction studies of ulnar nerve in patients with carpal tunnel syndrome

| Variables          | Group A (n = 40) | Group B (n = 33) |
|--------------------|------------------|------------------|
| Ulnar motor nerve  |                  |                  |
| DML (ms)           | 2.67±0.32        | 2.73±0.29        |
| CMAP (mV)          | 10.16±1.79       | 9.50±1.95        |
| BE-ML (ms)         | 5.07±0.53        | 5.73±0.98        |
| BE-CMAP (mV)       | 9.37±1.62        | 8.95±2.30        |
| BE-MCV (m/s)       | 58.15±5.99       | 59.84±7.62       |
| AE-ML (ms)         | 7.41±0.59        | 7.50±1.39        |
| AE-CMAP (mV)       | 9.00±1.64        | 8.62±2.63        |
| AE-MCV (m/s)       | 59.24±6.40       | 60.0±8.41        |

Table 4 Ultrasound measurements of patients with carpal tunnel syndrome

| Ultrasound parameters | Group A (n = 40) | Group B (n = 33) |
|-----------------------|------------------|------------------|
| DF-CSA (mm²)          | 6.26±1.64        | 6.15±1.86        |
| DF-P (mm)             | 10.42±1.80       | 10.56±1.82       |
| W-CSA (mm²)           | 12.45±3.97       | 16.54±6.81*      |
| W-P (mm)              | 16.67±2.80       | 19.64±4.08*      |
| R-CSA                 | 2.06±0.69        | 2.79±1.01        |
| R-P                   | 1.64±0.39        | 1.90±0.47        |
| ΔCSA (mm²)            | 6.17±3.76        | 10.40±6.13*      |
| ΔP (mm)               | 6.22±3.28        | 9.08±4.04*       |

*P < 0.05, vs. group A. Data are expressed as the mean ± SD (independent samples t-test). DF-CSA: Cross-sectional area of one third distal forearm; DF-P: perimeter of one third distal forearm; W-CSA: Wrist cross-sectional area; W-P: Wrist perimeter; R-CSA: ratio of cross-sectional area of wrist over one third distal forearm; R-P: ratio of perimeter of wrist over one third distal forearm; ΔCSA: changes of cross-sectional area from wrist to one third distal forearm; ΔP: changes of perimeter from wrist to one third distal forearm.

Table 5 Area under the curve (AUC) of ultrasound parameters in patients with carpal tunnel syndrome

| Ultrasound parameters | AUC | Asymptotic Sig. |
|-----------------------|-----|-----------------|
| W-CSA (mm²)           | 0.710±0.059 | 0.001           |
| W-P (mm)              | 0.748±0.056 | 0.000           |
| R-CSA                 | 0.725±0.056 | 0.001           |
| R-P                   | 0.676±0.060 | 0.007           |
| ΔCSA (mm²)            | 0.758±0.053 | 0.000           |
| ΔP (mm)               | 0.717±0.057 | 0.001           |

Table 6 Cut-off values with sensitivity and specificity using Receiver Operating Characteristics Curve

| Ultrasonic parameters | Cut-off values | Sensitivity (%) | Specificity (%) |
|-----------------------|----------------|-----------------|-----------------|
| W-CSA (mm²)           | 12.00          | 80.0            | 48.9            |
| W-P (mm)              | 16.27          | 88.6            | 51.1            |
| R-CSA                 | 1.85           | 85.7            | 48.9            |
| R-P                   | 1.48           | 80.0            | 40.0            |
| ΔCSA (mm²)            | 6.98           | 77.1            | 62.2            |
| ΔP (mm)               | 5.77           | 80.0            | 46.7            |

Discussion

Cut-off values for severity gradation vs. differentiation between demyelination and secondary axonal degeneration

CTS with secondary axonal degeneration is a more severe pathological stage compared to CTS with demyelination alone (Caetano, 2003). Our results consistently indicated that the grade of severity, NCS and US outcome in the group B were more inferior than those in the group A. Regarding cut-off values for severity gradation, Klauser et al. (2015) suggested 1.7 and 6 mm² as cut-off values of R-CSA and ΔCSA to distinguish mild from moderate CTS while 2.2 and 9 mm² to distinguish moderate from severe CTS. Baeie et al. (2015) revealed 12.95 (± 3.19) mm² as the mean value of CSA for moderate CTS. A recent study also revealed 16.0 (± 2.7) mm, 18.5 (± 3.4) mm and 19.7 (± 3.8) mm as cut-off values of W-P to classify the severity of CTS from mild, moderate to severe grade, indicating W-P and R-P as a potential ultrasound parameters for grading severity of CTS in a logistic regression model (Filius et al., 2015). These cut-off values for severity gradation match with the cut-off values identified in our studies to differentiate CTS with axonal degeneration, where R-CSA was recorded at 1.85, ΔCSA at 6.98 mm², CSA at 12.00 mm², and W-P at 16.27 mm respectively. In this study, R-CSA was 1.85, which is between 1.7 and 2.2; ΔCSA was 6.98 mm², which is between 6 mm² and 9 mm²; CSA was 12.00 mm², which is within the moderate grade, and W-P was 16.27 mm, which is estimated to be mild to moderate grade. These values may serve as clearer indicators to interpret the pathological progress based on the current ultrasound severity classification system. In this study, among hands with moderate CTS, R-CSA was 1.87 and 2.79, ΔCSA was 6.22 mm² and 9.56 mm², W-CSA was 13.5 (± 6.21) mm².
and 16.85 (± 10.67) mm², W-P was 18.11 mm and 19.68 mm respectively in group A and group B. If the above cut-off values were taken into account, then the treatment approaches may differ regardless of the same severity grade. Previous ultrasound studies mainly focused on exploring cut-off values for CTS severity gradation, however, different pathological progresses may co-exist within the same grade, as was also reflected from our identified cut-off values. These findings can help to locate ultrasound cut-off values for clearer pathological progress based on the current gradation system. It can further support a more refined treatment regime for future CTS patients, in particular for those who fulfill the surgical criteria but diagnosed as less severe grade.

Sensitivity, specificity, and accuracy of cut-off values for diagnostic confirmation, severity gradation versus differentiation between demyelination and secondary axonal degeneration

CSA has been mostly studied in previous studies for its use in the diagnostic confirmation and severity gradation. As for diagnostic confirmation, a variety of CSA values were explored, including 8.5 mm² (sensitivity 97%, specificity 98%, accuracy 97.2%) (Mohammadi et al., 2010), 9 mm² (sensitivity 65–100%, specificity 92.5–97%, accuracy 78.9%) (Duncan et al., 1999; Altinok et al., 2004), 10 mm² (sensitivity 82–82.8%, specificity 72.7–87%, accuracy 79.3–83.4%) (Wong et al., 2004; Ziswiler et al., 2005), 11 mm² (sensitivity 70–73%, specificity 57–63%) (Sarria et al., 2000; Swen et al., 2001), 12 mm² (sensitivity 67–83%, specificity 50–97%, accuracy 71.5–82%) (Nakamichi and Tachibana, 2002; Klauser et al., 2011), 13 mm² (sensitivity 86%, specificity 97%) (Fujimoto et al., 2015) and 15 mm² (sensitivity 88%, specificity 96%) (Lee et al., 1999). ΔCSA was reported to be 4 mm² for diagnostic confirmation (sensitivity 92.5%, specificity 96.4%, accuracy 93.9%) (Klauser et al., 2011). For severity gradation, the sensitivity, specificity, and accuracy of the method using 1.7 as the cut-off value of R-CSA to discriminate between mild and moderate CTS was 77%, 79% and 84.1%, respectively, while they were 53%, 84%, and 71% respectively for the method using 2.2 as the cut-off value of R-CSA (Klauser et al., 2015). As shown in Tables 5 and 6 in this study, by comparison with those for diagnostic confirmation, the performance of CSA in our study were comparable while ΔCSA appeared lower but still within acceptable range. In comparison with severity gradation, the sensitivity of R-CSA in our study was higher, while the accuracy was lower but acceptable. However, the specificity of R-CSA appeared lower than that in previous studies. As for ΔCSA, the sensitivity and accuracy in our study were comparable with that for severity gradation but lower in specificity. Overall, the sensitivity and accuracy of our suggested CSA (12 mm²), R-CSA (1.85) and ΔCSA (6.98 mm²) to differentiate demyelination from secondary axonal degeneration are comparable with those for diagnostic confirmation and severity gradation in previous studies. However, the fair specificity in our suggested cut-off values may be explained due to lack of the universal agreement upon differentiating demyelination from secondary axonal degeneration based on NCS test. In order to set up the criteria, we used previous clinical evidences, including those recommend
retrieval, data analysis, statistical analysis, and manuscript editing; XD: clinical and experimental studies, data acquisition, and manuscript preparation: all authors; manuscript review: XD, KPL, SWL, and WYJ; guarantor: WYJ. All authors approved the final version of this paper for publication.

Conflicts of interest: The authors declared no competing interest.

Financial support: None.

Research ethics: This study was approved by the Institutional Review Board of The University of Hong Kong/Hospital Authorities in Hong Kong West (HKU/HA HKW/IRB, Ref. Number: UW17-129), Hong Kong Special Administrative Region, China and performed in accordance with the Declaration of Helsinki. Declaration of patient consent: The authors certify that they have obtained all appropriate participant consent forms. In the form, the participants have given their consent for their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Data sharing statement: Individual participant data (including data dictionary) that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices) are available. Study Protocol, Analytic Case Report, and Clinical Study Report are shared. The data will be available beginning 9 months and ending 36 months following article publication for researchers who provide a methodologically sound proposal for individual participant data meta-analysis. Proposals may be submitted up to 36 months following article publication. After 36 months the data will be available in our University’s data warehouse but without investigator support other than deposited metadata.

Plagiarism check: Checked twice by iThenticate.

Peer review: Externally peer reviewed.

Open access statement: This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under identical terms.

References

Altimini T, Baysal O, Karakas H, Sigirci A, Alkan, Aykhan A (2004) Ultrasonographic assessment of mild and moderate idiopathic carpal tunnel syndrome. Clin Radiol 59:916-925.

Azami A, Maleki N, Anari H, Iranparvar, Alamard M, Kalantarhormozi M, Tavosi Z (2014) The diagnostic value of ultrasound compared with nerve conduction velocity in carpal tunnel syndrome. Int J Rheum Dis 17:612-620.

Baiee RH, AL-Mukhtar NJ, Al-Rubiae SJ, Hammoodi ZH, Abass FN (2015) Comparative study between clinical and ultrasound findings in patients with carpal tunnel syndrome. J Orthop Res 33:1332-1340.

Bland JD (2000) A neurophysiological grading scale for carpal tunnel syndrome. Muscle Nerve 24:1280-1283.

Baiee RH, AL-Mukhtar NJ, Al-Rubiae SJ, Hammoodi ZH, Abass FN (2015) Multidimensional ultrasound imaging of the median nerve conduction in carpal tunnel syndrome patients with suspected carpal tunnel syndrome. BMC Musculoskelet Disord 14:236.

Baiee RH, AL-Mukhtar NJ, Al-Rubiae SJ, Hammoodi ZH, Abass FN (2015) Multidimensional ultrasound imaging of the median nerve conduction in carpal tunnel syndrome patients with suspected carpal tunnel syndrome. BMC Musculoskelet Disord 14:236.

Baiee RH, AL-Mukhtar NJ, Al-Rubiae SJ, Hammoodi ZH, Abass FN (2015) Multidimensional ultrasound imaging of the median nerve conduction in carpal tunnel syndrome patients with suspected carpal tunnel syndrome. BMC Musculoskelet Disord 14:236.

Baiee RH, AL-Mukhtar NJ, Al-Rubiae SJ, Hammoodi ZH, Abass FN (2015) Multidimensional ultrasound imaging of the median nerve conduction in carpal tunnel syndrome patients with suspected carpal tunnel syndrome. BMC Musculoskelet Disord 14:236.

Baiee RH, AL-Mukhtar NJ, Al-Rubiae SJ, Hammoodi ZH, Abass FN (2015) Multidimensional ultrasound imaging of the median nerve conduction in carpal tunnel syndrome patients with suspected carpal tunnel syndrome. BMC Musculoskelet Disord 14:236.